Lakefront Biotherapeutics NV (LKFT) - Net Assets
Based on the latest financial reports, Lakefront Biotherapeutics NV (LKFT) has net assets worth $3.26 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.35 Billion) and total liabilities ($87.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Lakefront Biotherapeutics NV balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.26 Billion |
| % of Total Assets | 97.39% |
| Annual Growth Rate | 8.6% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.59 |
Lakefront Biotherapeutics NV - Net Assets Trend (2022–2025)
This chart illustrates how Lakefront Biotherapeutics NV's net assets have evolved over time, based on quarterly financial data. Also explore net asset growth rate of Lakefront Biotherapeutics NV to track the company's year-over-year net asset growth rate.
Annual Net Assets for Lakefront Biotherapeutics NV (2022–2025)
The table below shows the annual net assets of Lakefront Biotherapeutics NV from 2022 to 2025. For live market cap and overall valuation, see LKFT market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.24 Billion | +11.70% |
| 2024-12-31 | $2.90 Billion | +3.63% |
| 2023-12-31 | $2.80 Billion | +10.67% |
| 2022-12-31 | $2.53 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lakefront Biotherapeutics NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 70726600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $210.58 Million | 6.51% |
| Common Stock | $293.94 Million | 9.08% |
| Other Comprehensive Income | $-5.64 Million | -0.17% |
| Other Components | $2.74 Billion | 84.58% |
| Total Equity | $3.24 Billion | 100.00% |
Lakefront Biotherapeutics NV Competitors by Market Cap
The table below lists competitors of Lakefront Biotherapeutics NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Cisri Gaona Materials Tech
SHE:300034
|
$1.76 Billion |
|
Engineers India Limited
NSE:ENGINERSIN
|
$1.76 Billion |
|
Shandong Pharmaceutical Glass Co Ltd
SHG:600529
|
$1.76 Billion |
|
China National Gold Group Gold Jewellery Co Ltd
SHG:600916
|
$1.76 Billion |
|
Genesis Energy LP
NYSE:GEL
|
$1.76 Billion |
|
BTG Hotels Group Co Ltd
SHG:600258
|
$1.75 Billion |
|
Zhejiang Jinke Peroxides Co Ltd
SHE:300459
|
$1.75 Billion |
|
Shenzhen Topband Co Ltd
SHE:002139
|
$1.75 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lakefront Biotherapeutics NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,896,939,000 to 3,235,868,000, a change of 338,929,000 (11.7%).
- Net income of 320,884,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 5,640,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $320.88 Million | +9.92% |
| Other Comprehensive Income | $-5.64 Million | -0.17% |
| Other Changes | $23.68 Million | +0.73% |
| Total Change | $- | 11.70% |
Book Value vs Market Value Analysis
This analysis compares Lakefront Biotherapeutics NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.70x to 0.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $38.47 | $26.81 | x |
| 2023-12-31 | $42.43 | $26.81 | x |
| 2024-12-31 | $43.80 | $26.81 | x |
| 2025-12-31 | $49.10 | $26.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lakefront Biotherapeutics NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.92%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.85%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.05x
- Recent ROE (9.92%) is above the historical average (2.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -8.63% | -90.36% | 0.05x | 1.87x | $-470.59 Million |
| 2023 | 7.57% | 88.31% | 0.06x | 1.56x | $-67.86 Million |
| 2024 | 2.56% | 26.88% | 0.07x | 1.43x | $-215.61 Million |
| 2025 | 9.92% | 28.85% | 0.33x | 1.05x | $-2.70 Million |
Industry Comparison
This section compares Lakefront Biotherapeutics NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $121,148,904
- Average return on equity (ROE) among peers: -45.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lakefront Biotherapeutics NV (LKFT) | $3.26 Billion | -8.63% | 0.03x | $1.76 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $102.55 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $67.72 Million | -21.45% | 0.18x | $283.63 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $151.68 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $828.08 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.12 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $30.68 Million | -84.47% | 0.32x | $3.37 Billion |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more